Adalimumab treatment for life threatening pulmonary artery aneurysm in Behçet disease: a case report

Behςet's disease (BD) is a multisystem disorder characterized by vasculitis. Pulmonary vascular problems such as pulmonary artery aneurysms (PAA) are reported to indicate poor prognosis and high mortality. We describe a 43-year-old man who presented with life threatening bilateral PAA and throm...

Full description

Saved in:
Bibliographic Details
Published in:Clinical rheumatology 2010, Vol.29 (1), p.91-93
Main Authors: Lee, Sung-Won, Lee, Sang-Yeob, Kim, Ki-Nam, Jung, Jin-Kyu, Chung, Won-Tae
Format: Article
Language:English
Subjects:
Adalimumab
Adult
Aneurysm - diagnostic imaging
Aneurysm - drug therapy
Aneurysm - etiology
Anti-Inflammatory Agents - therapeutic use
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Behcet Syndrome - complications
Behcet Syndrome - diagnostic imaging
Behcet Syndrome - drug therapy
Case Report
Cyclophosphamide - therapeutic use
Drug Therapy, Combination
Humans
Immunosuppressive Agents - therapeutic use
Male
Medicine
Medicine & Public Health
Prednisone - therapeutic use
Pulmonary Artery - diagnostic imaging
Rheumatology
Tomography, X-Ray Computed
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Behςet's disease (BD) is a multisystem disorder characterized by vasculitis. Pulmonary vascular problems such as pulmonary artery aneurysms (PAA) are reported to indicate poor prognosis and high mortality. We describe a 43-year-old man who presented with life threatening bilateral PAA and thromboembolic disease due to BD. He was treated with prednisone and pulse cyclophosphamide and was poorly responsive to the conventional immunosuppression. The introduction of adalimumab therapy stabilized his PAA. We report that the inhibition of TNF-α using the neutralizing monoclonal antibody adalimumab has the potential to induce rapid, complete, and long-lasting remission in a life-threatening manifestation of BD.
ISSN:0770-3198
1434-9949
DOI:10.1007/s10067-009-1272-2